Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Section 3 of 6

Product information and disease description

395 evidence topics · 153 sources

Product description

Phase of product development

Summary

Mineralys Therapeutics submitted a New Drug Application (NDA) for lorundrostat to the FDA in December 2025 for “the treatment of hypertension in combination with other antihypertensive drugs”. The FDA accepted the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026. The company described the application as still under review in its third quarter 2026 results announcement and in its release on the Transform-HTN results presented on November 8, 2026. According to the company, the NDA includes the pivotal Launch-HTN (phase 3) and Advance-HTN (phase 2) trials, the Explore-CKD proof-of-concept trial, and the Transform-HTN open-label extension trial; the Explore-OSA trial was not part of the original application. In its 2026 Form 10-Q, the company described an advisory committee meeting as “not anticipated currently”. No FDA expedited program designation and no marketing application outside the United States was found. The company has stated no launch date; it describes its commercial preparations as on track for “launch upon approval”. In its third quarter 2025 results announcement, the company had planned the submission for “near the end of 2025 or during the first quarter of 2026”.

Regulatory status: Under review; NDA submitted December 2025, PDUFA target action date December 2026
Launch

No evidence found.

Commercial launch preparation: launch planned upon approval, no date stated
Trials included in the NDA
FDA expedited program designations (Fast Track, Breakthrough Therapy, Priority Review)

No evidence found.

Marketing applications outside the United States

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Brand name

No evidence found.

Dosage forms and strengths
Doses studied in phase 2 and phase 3 trials: 12.5 mg to 100 mg
Commercial strengths and package sizes

No evidence found.

Average sales price and wholesale acquisition cost
Wholesale acquisition cost and average sales price of lorundrostat

No evidence found.

American hospital formulary service (AHFS), or other drug classification
AHFS classification

No evidence found.

Indication
Pharmacology
Mechanism of action
In vitro potency and selectivity over 11β-hydroxylase (CYP11B1)
Pharmacodynamics
Plasma renin activity, 11-deoxycorticosterone, serum potassium, and natriuresis in healthy participants

“Once‐daily administration of lorundrostat at doses ranging from 40 to 360 mg increased plasma renin activity and serum 11‐DOC compared with placebo (Figure 3a,b). Elevations in serum potassium concentrations due to lorundrostat‐mediated reductions in PAC were mild and seen across all doses tested (Figure 3c). These effects declined during the washout period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Urine sodium and urinary log10 (10 × Na+/K+) ratio were increased at all dose levels tested in the SAD, consistent with reduced aldosterone signaling (Figure 3d).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Within 2 days of initiation of lorundrostat treatment, serum potassium rose in all three dose cohorts (part 2) by group mean values ranging from 0.28 to 0.38 mmol/L and remained elevated throughout the remainder of the 7 days of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Given that the PD effects on renal electrolyte regulation were near maximum at 120 mg daily and the excessive 11‐DOC accumulation observed at dose of 360 mg once daily, the data suggest that the dose selection for the treatment of hypertension should avoid the higher dose level and focus on doses up to 120 mg daily.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Aldosterone, plasma renin activity, and aldosterone-renin ratio through week 48: Transform-HTN
BiomarkerPercent change in geometric mean from Launch-HTN baseline at week 48
Serum aldosterone“-54.8%”
Plasma renin activity“+123.9%”
Aldosterone-renin ratio“-79.8%”
Pharmacokinetics
Metabolism, protein binding, and volume of distribution

No evidence found.

Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information, contraindications, and boxed warnings

Not applicable.

Adverse events of special interest: Launch-HTN
Hyperkalemia: Launch-HTN
Adverse events during 36 weeks of open-label treatment: Transform-HTN
EventLorundrostat (N=632), n (%)
Any serious adverse event“27 (4.3)”
Treatment-emergent adverse event leading to study drug withdrawal“37 (5.9)”
Hyperkalemia leading to study drug withdrawal“10 (1.6)”
Hyperkalemia requiring modification of trial drug“32 (5.1)”
Hyponatremia requiring modification of trial drug“28 (4.4)”
Hypotension with symptoms“13 (2.1)”
Serum potassium >6.0 mmol/L confirmed by repeat testing“16 (2.5)”
Decline in estimated glomerular filtration rate
Adrenal insufficiency and cortisol
Special populations
Age, sex, race, and body mass index: Launch-HTN subgroups
Hepatic impairment

No evidence found.

Drug/Drug, drug/disease interactions
Effects of other drugs on Lorundrostat
Clinical drug-drug interaction studies

No evidence found.

Effects of Lorundrostat on other drugs
Clinical drug-drug interaction studies

No evidence found.

Dosing and administration
Dosage
Proposed labeled dose

No evidence found.

Administration
Access and distribution
Specialty pharmacy or limited distribution network

No evidence found.

Co-prescribed/Concomitant therapies
Launch-HTN: background drug classes and other medications at randomization, No. (%)
MedicationLorundrostat 50 mg and then 100 mg (n = 270)Lorundrostat 50 mg (n = 541)Placebo (n = 272)
Taking 2 antihypertensive medications“106 (39.3)”View highlighted excerpt for this quote“213 (39.4)”View highlighted excerpt for this quote“113 (41.5)”View highlighted excerpt for this quote
Taking ≥3 antihypertensive medications“164 (60.7)”View highlighted excerpt for this quote“328 (60.6)”View highlighted excerpt for this quote“159 (58.5)”View highlighted excerpt for this quote
Thiazide or thiazide-like diuretic“259 (95.9)”View highlighted excerpt for this quote“520 (96.1)”View highlighted excerpt for this quote“259 (95.2)”View highlighted excerpt for this quote
ACE inhibitor or ARB“237 (87.8)”View highlighted excerpt for this quote“467 (86.3)”View highlighted excerpt for this quote“225 (82.7)”View highlighted excerpt for this quote
Calcium channel blocker“140 (51.9)”View highlighted excerpt for this quote“278 (51.4)”View highlighted excerpt for this quote“135 (49.6)”View highlighted excerpt for this quote
Glucagon-like peptide-1 receptor agonists“13 (4.8)”View highlighted excerpt for this quote“30 (5.6)”View highlighted excerpt for this quote“9 (3.3)”View highlighted excerpt for this quote
Sodium-glucose cotransporter 2 inhibitors“14 (5.2)”View highlighted excerpt for this quote“21 (3.9)”View highlighted excerpt for this quote“13 (4.8)”View highlighted excerpt for this quote
Effect of Lorundrostat on quality measures
Product-specific effect on quality measures

No evidence found.

Product comparison
Summary: lorundrostat and the add-on options for uncontrolled hypertension
  • Approved add-on drugs with a labeled hypertension indication: baxdrostat (BAXFENDY, aldosterone synthase inhibitor, FDA-approved May 2026, 1 mg or 2 mg once daily), aprocitentan (TRYVIO, endothelin receptor antagonist, 12.5 mg once daily, boxed warning for embryo-fetal toxicity), spironolactone (ALDACTONE, labeled “as add-on therapy for the treatment of hypertension”), and eplerenone (INSPRA, 50 mg once daily, up to 50 mg twice daily). Two renal denervation systems received FDA premarket approval in November 2023 as “adjunctive treatment” when lifestyle modifications and antihypertensive medications do not control blood pressure.
  • Placebo-adjusted change in office systolic blood pressure in the pivotal trials: baxdrostat -9.8 mmHg (2 mg) and -8.7 mmHg (1 mg) at week 12 in BaxHTN; aprocitentan 12.5 mg -3.8 mmHg at week 4; lorundrostat 50 mg -9.1 mm Hg at week 6 in Launch-HTN. The trials differ in time point, measurement method, and background therapy, and no head-to-head trial of lorundrostat against another add-on drug was identified.
  • Indirect comparisons: in a drug-level network meta-analysis of 10 trials (2,865 participants) with resistant hypertension, the mean differences in office systolic blood pressure versus placebo were -14.08 mmHg (amiloride), -10.78 mmHg (spironolactone), -9.09 mmHg (baxdrostat), -8.14 mmHg (eplerenone), and -6.80 mmHg (lorundrostat). ICER rated the evidence “insufficient” (I) for baxdrostat versus lorundrostat in all three of its populations, “Promising but Inconclusive” (P/I) for either drug versus spironolactone, eplerenone, or amiloride in Populations 1 and 2, and “comparable or inferior” (C-) versus amlodipine in Population 3.
  • Hyperkalemia in ICER's comparison table: baxdrostat 6.6% (1 mg) and 10.2% (2 mg) against 2.5% with placebo; lorundrostat 50 mg 2.5% against 0.3% with placebo.
Baxdrostat (BAXFENDY): prescribing information
FieldQuoted label text
Indication“BAXFENDY is an aldosterone synthase inhibitor indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other agents.”
Recommended dosage“The recommended dosage of BAXFENDY is 2 mg orally once daily.”
Dosage at increased risk of hyperkalemia or hyponatremia“For patients at increased risk of hyperkalemia or hyponatremia, the recommended dosage is 1 mg orally once daily”
Strengths“Tablets: 1 mg and 2 mg”
Contraindications“None.”
Warnings and precautions“Hyperkalemia: Assess serum potassium before initiation and periodically thereafter.”
Warnings and precautions“Hyponatremia: Assess serum sodium before initiation and periodically thereafter.”
Most common adverse reaction“The most common adverse reaction (more frequent than placebo and ≥ 5% in BAXFENDY-treated patients) was hyperkalemia.”
Drug interactions“Strong and moderate CYP3A inducers: Monitor the therapeutic effect of BAXFENDY more frequently during concomitant use.”
Renal impairment“Safety and effectiveness of BAXFENDY initiated in patients with eGFR < 45 mL/min/1.73 m2 have not been established”
Elimination half-life“The mean effective half-life of baxdrostat was approximately 26 hours (range 23 to 32 hours).”
Cardiovascular outcomes“There are no controlled trials demonstrating risk reduction of these events with BAXFENDY.”
Aprocitentan (TRYVIO, Idorsia): prescribing information
Zilebesiran (Alnylam and Roche): investigational subcutaneous siRNA against angiotensinogen
ICER network meta-analysis, Population 3 (not at goal on two drugs, third first-line agent not yet tried): systolic blood pressure versus placebo
Add-on drugMean difference versus placebo, mm Hg (95% credible interval)
Baxdrostat“-10.1 (-16.6, -3.9)”
Lorundrostat“-8.6 (-12.4, -4.8)”
Amlodipine“-8.3 (-10.7, -6.2)”

Place of product in therapy

Disease description

Definition and etiology
Primary aldosteronism in resistant hypertension: cohort studies with confirmatory testing
Epidemiology
Incidence of hypertension
Prevalence of hypertension
Natural history, survival, and mortality
Pathophysiology
Mineralocorticoid receptor activation and target organ injury
Renin suppression and sodium retention in resistant hypertension
Diagnosis
Out-of-office thresholds corresponding to office blood pressure
Office, mm HgHBPM, mm HgDaytime ABPM, mm HgNighttime ABPM, mm Hg24-Hour ABPM, mm Hg
“130/80”“130/80”“130/80”“110/65”“125/75”
“140/90”“135/85”“135/85”“120/70”“130/80”
Pseudoresistance: confirmation of true treatment resistance
Medication nonadherence: prevalence and adherence testing
Clinical presentation - signs and symptoms
Long-term morbidity
Burden of hypertension
Humanistic burden and health-related quality of life
Health-related quality of life and SF-6D utility in apparent treatment-resistant hypertension on four or more drug classes: MEPS 2000 to 2011
EQ-5D index scores for hypertension and its cardiovascular complications: US catalogue from MEPS 2000 to 2002
Economic burden and healthcare resource utilization
US spending on treatment of hypertension by type of care and payer, 2019
Resource use and costs with uncontrolled compared with controlled blood pressure in apparent treatment-resistant hypertension and stage 3 or 4 CKD: US claims, 3966 patients
Annual costs of cardiovascular health states used in the ICER model, 2025 US dollars
Health stateDirect medical costProductivity cost (modified societal perspective)
Hypertension (annual)“$3,211”Not reported
Stroke (acute and annual; annual for productivity)“$20,442 / $20,697”“$16,781”
Myocardial infarction (acute and annual; annual for productivity)“$25,832 / $17,106”“$19,028”
Coronary heart disease (annual)“$13,798”“$7,092”
Heart failure (index hospitalization and annual; annual for productivity)“$16,671 / $33,890”“$16,004”
End-stage kidney disease (annual)“$108,953”“$17,650”
Economic impact of hypertension on families
Out-of-pocket share of US spending on treatment of hypertension, 2019
Caregiver time and cost burden in uncontrolled or resistant hypertension

No evidence found.

Economic impact of diagnostic testing
Cost-effectiveness of primary aldosteronism screening and subtype diagnosis in resistant hypertension: US decision model
Test or procedure (CPT or DRG codes as printed)Base-case cost
Screening aldosterone to renin ratio (CPT 82088, 84244, 84132)“$93”View highlighted excerpt for this quote
Confirmatory saline infusion testing (CPT 96365, 93666)“$141”View highlighted excerpt for this quote
Abdominal CT (CPT 74170)“$329”View highlighted excerpt for this quote
Adrenal venous sampling (CPT 75893, 36500)“$2,645”View highlighted excerpt for this quote
Adrenalectomy, surgery and anesthesia (CPT 60650, 00866)“$3,054”View highlighted excerpt for this quote
One year cost of spironolactone“$158”View highlighted excerpt for this quote

Approaches to treatment

Current treatment options and standard of care
Lifestyle and dietary interventions
Thiazide-type diuretics, Renin-Angiotensin system inhibitors, and calcium channel blockers
Steroidal mineralocorticoid receptor antagonists
Comparators for aldosterone synthase inhibitors and hyperkalemia rates: ICER evidence report
Drug and armParticipants (n)Hyperkalemia at 12 weeks (%)
Spironolactone 15 to 50 mg“2748”“17.5”
Placebo (spironolactone studies)“2760”“7.5”
Eplerenone 25 to 50 mg“5282”“5”
Placebo (eplerenone studies)“5275”“2.6”
Generic spironolactone and eplerenone costs: ICER evidence report
DrugWAC per doseNet price per year
Spironolactone 25 mg“$0.117”“$43”
Spironolactone 100 mg“$0.4683”“$171”
Eplerenone 50 mg“$1.3997”“$511”
Eplerenone 100 mg“$2.793”“$1,022”
Epithelial sodium channel blockers
Amiloride versus spironolactone: randomized noninferiority trial

“Prospective, open-label, blinded end-point randomized clinical trial conducted at 14 sites in South Korea. From November 16, 2020, to February 29, 2024, 118 patients with home SBP of 130 mm Hg or greater after a 4-week run-in period with a fixed-dose triple medication combination (angiotensin receptor blocker, calcium channel blocker, and thiazide) were enrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients were randomized in a 1:1 ratio to receive 12.5 mg/d of spironolactone (n = 60) or 5 mg/d of amiloride (n = 58). If home SBP remained 130 mm Hg or greater and serum potassium was less than 5.0 mmol/L after 4 weeks, dosages were increased to 25 mg/d and 10 mg/d, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At week 12, mean home SBP measurements were changed from baseline by −13.6 (SD, 8.6) mm Hg and −14.7 (SD, 11.0) mm Hg in the amiloride and spironolactone groups, respectively (between-group difference in change, −0.68 mm Hg; 90% CI, −3.50 to 2.14 mm Hg), with amiloride demonstrating noninferiority to spironolactone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“One case of hyperkalemia-related discontinuation occurred in the amiloride group, with no cases of gynecomastia in either group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Generic amiloride costs: ICER evidence report
DrugWAC per doseNet price per year
Amiloride 5 mg“$0.5627”“$206”
Amiloride 10 mg“$1.1253”“$411”
Aldosterone synthase inhibitors
Endothelin receptor antagonists
Aprocitentan: PRECISION trial in resistant hypertension

“Patients were eligible for randomisation if their sitting systolic blood pressure was 140 mm Hg or higher despite taking standardised background therapy consisting of three antihypertensive drugs, including a diuretic.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The least square mean (SE) change in office systolic blood pressure at 4 weeks was -15·3 (SE 0·9) mm Hg for aprocitentan 12·5 mg, -15·2 (0·9) mm Hg for aprocitentan 25 mg, and -11·5 (0·9) mm Hg for placebo, for a difference versus placebo of -3·8 (1·3) mm Hg (97·5% CI -6·8 to -0·8, p=0·0042) and -3·7 (1·3) mm Hg (-6·7 to -0·8; p=0·0046), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The respective difference for 24 h ambulatory systolic blood pressure was -4·2 mm Hg (95% CI -6·2 to -2·1) and -5·9 mm Hg (-7·9 to -3·8).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“After 4 weeks of withdrawal, office systolic blood pressure significantly increased with placebo versus aprocitentan (5·8 mm Hg, 95% CI 3·7 to 7·9, p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The most frequent adverse event was mild-to-moderate oedema or fluid retention, occurring in 9%, 18%, and 2% for patients receiving aprocitentan 12·5 mg, 25 mg, and placebo, during the 4-week double-blind part, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Beta-blockers, alpha-blockers, central sympatholytics, and direct vasodilators
Renal denervation
Medicare coverage with evidence development: CMS national coverage decision

“The Centers for Medicare & Medicaid Services (CMS) will cover radiofrequency renal denervation (rfRDN) and ultrasound renal denervation (uRDN) (collectively, RDN) for uncontrolled hypertension under Coverage with Evidence Development (CED) according to the provisions in sections (B) and (C) below.” (opens the source at this quote in a new tab)

“(a) Diagnosis of uncontrolled hypertension (≥ 140 mm Hg systolic blood pressure and > 90 mm Hg diastolic blood pressure) despite active management by a clinician with primary responsibility for blood pressure management.” (opens the source at this quote in a new tab)

“(c) On lifestyle modifications and stable doses of maximally tolerated guideline-directed medical therapy (GDMT), with assessment of adherence to the prescribed regimen, for at least six weeks before referral for RDN.” (opens the source at this quote in a new tab)

“At a minimum, patients must be screened for primary aldosteronism, obstructive sleep apnea, and drug or alcohol induced hypertension before referral to RDN.” (opens the source at this quote in a new tab)

“The primary clinicians must coordinate management of the patient for a minimum of six months before referral for RDN, during which the patient had at least three encounters, with no more than two of the three encounters being virtual.” (opens the source at this quote in a new tab)

Limitations of current therapies
Summary
  • Blood pressure control: In NHANES data from August 2021 to August 2023, 20.7% of US adults with hypertension had blood pressure controlled to less than 130/80 mm Hg, with no significant change from 2017 to March 2020 (22.2%). In a separate NHANES analysis, the age-adjusted proportion with controlled blood pressure declined from 53.8% in 2013 to 2014 to 43.7% in 2017 to 2018. ICER states that more than 70% of adults with hypertension remain above goal and names clinical inertia, pill burden, additive copays, variable tolerance of side effects, and low awareness as contributors.
  • Underuse of aldosterone-targeted therapy: Among NHANES adults with apparent treatment-resistant hypertension, 8.3% were taking a mineralocorticoid receptor antagonist, rising from 6.3% in 2003 to 2004 to 13.3% in 2017 to 2020. Among US Veterans with apparent treatment-resistant hypertension, 4,277 (1.6%) were tested for primary aldosteronism, and testing was associated with a 4-fold higher likelihood of starting a mineralocorticoid receptor antagonist (hazard ratio 4.10).
  • Tolerability of fourth-line options: The 2025 AHA/ACC guideline states that 4% to 40% of adults with resistant hypertension cannot tolerate spironolactone because of hyperkalemia or antiandrogenic side effects, and that randomized trials have not demonstrated a reduction in home or 24-hour blood pressure with eplerenone at 25 to 100 mg daily compared with placebo. ICER reports gynecomastia rates of 3.9% to 6% with spironolactone in observational hypertension studies. Patient groups told ICER that clinicians are often reluctant to start spironolactone because of potential side effects. With baxdrostat, hyperkalemia led to discontinuation in 5.7% of participants in the BaxHTN long-term extension (safety data to 54 weeks), and serum potassium above 6 mmol/L occurred in 9.5% of the pooled baxdrostat arm and 0.8% of the placebo arm. Edema or fluid retention occurred in 9% of participants receiving aprocitentan at the approved 12.5 mg dose and 2% receiving placebo. ICER describes beta-blockers, alpha blockers, and central sympatholytic drugs as less efficacious and less well tolerated, and the guideline reserves renal denervation for adults with intolerable side effects to optimal drug regimens.
  • Adherence and discontinuation: The weighted national nonadherence rate among 23.8 million adults with hypertension who filled antihypertensive prescriptions was 31.0%. A meta-analysis of 24 studies in apparent treatment-resistant hypertension estimated a pooled nonadherence prevalence of 31.2% (range 3.3% to 86.1%). Among Medicare beneficiaries starting antihypertensive treatment, discontinuation was 21.0% in 2007 and 21.3% in 2012, and low adherence fell from 37.4% in 2007 to 31.7% in 2012.
  • Therapeutic inertia and access: ICER reports hearing that it often takes three to six months to adjust or add a medication in people with uncontrolled hypertension, and patients described readings above 140 mm Hg that were not acted on. The guideline links clinical inertia, among other factors, to the higher frequency of resistant hypertension in Black populations. Patients told ICER that prior authorization and step therapy can lead people to abandon treatment.
Place in treatment, anticipated use, and care setting
Summary
  • Guideline sequence: The 2025 AHA/ACC guideline starts drug treatment of resistant hypertension with an ACE inhibitor or ARB, a calcium channel blocker, and a diuretic, then adds spironolactone (25 to 50 mg/day) as the fourth drug. Amiloride (10 to 20 mg) is the alternative when spironolactone or eplerenone is not tolerated, followed by beta-blockers, alpha blockers, central sympatholytic drugs, direct vasodilators, or aprocitentan. Renal denervation is reserved for adults with intolerable side effects to optimal drug regimens. ICER summarizes the guideline as recommending referral to a specialist for a known or suspected secondary cause or when blood pressure remains uncontrolled after more than 6 months of treatment.
  • Anticipated use: Mineralys submitted the NDA for the treatment of hypertension in combination with other antihypertensive drugs, the same wording as the first part of the BAXFENDY (baxdrostat) indication, which adds adults not adequately controlled on other agents. Mineralys describes its target as third-line or later treatment, with resistant hypertension as the initial segment and a “beachhead at fourth line”. Manufacturers told ICER that they view aldosterone synthase inhibitors as appropriate for third- or fourth-line therapy regardless of whether a third first-line agent had been tried.
  • ICER populations and clinical input: ICER assessed three populations: resistant hypertension not at goal; blood pressure above goal on two drugs with intolerance of a third first-line agent; and blood pressure above goal on two drugs without a trial of a third first-line agent. ICER consulted five clinical experts (two internists, two cardiologists, one nephrologist), who identified mineralocorticoid receptor antagonists such as spironolactone as the preferred option for people who remain uncontrolled despite regular medication use.
  • Care setting: Lorundrostat is orally administered. Mineralys estimates about 60,000 physicians write half of the third-line or later prescriptions, with a 60/40 split between primary care and specialists, most of whom are cardiologists. The guideline assigns routine and complex hypertension care to primary care physicians and cardiologists, and complex care involving secondary causes or resistant hypertension to nephrologists, endocrinologists, and hypertension specialists.
Heterogeneity of treatment effect
Summary
  • Lorundrostat: In Launch-HTN, the blood pressure effect of lorundrostat 50 mg was consistent across age, sex, race, body mass index, and number of background antihypertensive drugs. The placebo-adjusted change in office systolic blood pressure at week 6 was −8.8 mm Hg in participants taking 2 drugs and −9.0 mm Hg in those taking 3 or more. In a Launch-HTN analysis by chronic kidney disease (CKD) status, the placebo-adjusted reduction at week 12 was −12.2 mm Hg without CKD and −9.6 mm Hg with CKD stages 1 to 3; confirmed serum potassium above 6.0 mmol/L occurred in 3 (2.4%) participants with CKD and none without CKD. In the phase 2 Target-HTN trial, prespecified exploratory subgroups showed larger reductions in participants with a body mass index above 30 than in those with a body mass index of 25 to 30, and attenuated reductions in participants not taking a diuretic; participants with nonsuppressed plasma renin (exploratory cohort 2) had a reduction similar to those with suppressed renin at 100 mg. In Explore-OSA, participants with obesity and moderate-to-severe obstructive sleep apnea had a placebo-adjusted office systolic reduction of 10.1 mm Hg in the parallel-arm analysis.
  • Class evidence: ICER reported consistent baxdrostat effects across all prespecified subgroups in BaxHTN and Bax24, similar aldosterone synthase inhibitor effects in participants taking two versus three or more background drugs, and no differential blood pressure lowering by mineralocorticoid antagonists between resistant and non-resistant hypertension. In a randomized crossover trial in resistant hypertension, spironolactone lowered blood pressure most across the distribution of baseline plasma renin, with a margin of superiority many-fold greater at the lower end, and plasma renin and the aldosterone-to-renin ratio predicted the home systolic response.
  • Limits of the evidence: The pivotal aldosterone synthase inhibitor trials excluded people with advanced CKD. ICER reports hearing that differences in treatment effect by race or ethnicity are small and not likely to be clinically significant. Target-HTN subgroup analyses were exploratory.
Lorundrostat by chronic kidney disease stage in Launch-HTN: placebo-adjusted change at week 12
CKD stageLorundrostat 50 mg participantsPlacebo-adjusted AOSBP change, mm Hg (95% CI)Week 12 % with AOSBP <130 mmHg, lorundrostat 50 mg
No CKD“N=406”“-12.2 (-17.1, -7.3)”“48.0”
Stage 1“N=58”“-10.6 (-18.6, -2.6)”“50.6”
Stage 2“N=31”“-7.6 (-16.5, 1.4)”“28.4”
Stage 3“N=38”“-10.1 (-21.1, 1.0)”“47.0”
Care management intervention strategies
Summary
  • Team-based care: The 2025 AHA/ACC guideline describes multidisciplinary team-based care, including pharmacists, nurses, and community health workers, as effective in addressing barriers to blood pressure control. In a meta-analysis of 19 studies (5,993 participants), team-based care lowered systolic blood pressure at 12 months by 10.5 mm Hg with non-physician medication titration and 5.0 mm Hg with physician titration compared with usual care; the non-physician titration strategy was estimated at $4,400 per QALY gained over 10 years.
  • Pharmacist management: In a cluster-randomized trial of 319 Black men recruited in 52 barbershops, pharmacist-led drug management reduced systolic blood pressure by 21.6 mm Hg more than the control approach at 6 months. A model estimated that 50% uptake of pharmacist prescribing would save $1.137 trillion and 30.2 million life years over 30 years.
  • Home blood pressure monitoring and adherence: The guideline states that home blood pressure monitoring improves office blood pressure control when combined with other interventions, and lists dose consolidation, single-pill combinations, pharmacist education, home monitoring with feedback, shared decision-making, and medication synchronization and reminders as evidence-based adherence strategies.
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy
Summary
  • Benefit per unit of blood pressure reduction: An individual participant-level meta-analysis of 48 trials found that each 5 mm Hg reduction in systolic blood pressure lowered the risk of major cardiovascular events by about 10%, with reductions of 13% for stroke, 13% for heart failure, 8% for ischemic heart disease, and 5% for cardiovascular death, irrespective of prior cardiovascular disease. A meta-analysis of 123 studies (613,815 participants) found that each 10 mm Hg reduction lowered major cardiovascular events (relative risk 0.80), coronary heart disease (0.83), stroke (0.73), heart failure (0.72), and all-cause mortality (0.87), with no significant effect on renal failure. FDA guidance attributes these benefits largely to the decrease in blood pressure itself across drug classes.
  • Lorundrostat: In Launch-HTN, lorundrostat 50 mg lowered office systolic blood pressure by 9.1 mm Hg more than placebo at week 6. No trial of lorundrostat or baxdrostat reporting cardiovascular, kidney, or mortality outcomes was identified; the placebo-controlled Launch-HTN comparison lasted 12 weeks.
  • Blood pressure as a surrogate: ICER states that blood pressure is a surrogate marker, that not all blood pressure drugs have the same effect on major adverse cardiovascular events and their effects on mortality are inconsistent, and that longer-term data are needed to determine the effect of aldosterone synthase inhibitors on patient-important outcomes. A review of FDA surrogate endpoints found 10 meta-analyses with inconsistent evidence on the strength of association between blood pressure reductions and cardiovascular outcomes and all-cause mortality. The Explore-OSA investigators state that a longer-term cardiovascular outcomes trial of lorundrostat should be considered.